Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study-Reference-Cited by-同舟云学术

Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study

Published:2021-03-01 Issue:5 Volume:203 Page:553-564
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Martinez Fernando J.¹,Rabe Klaus F.²,Ferguson Gary T.³,Wedzicha Jadwiga A.⁴,Singh Dave⁵,Wang Chen⁶,Rossman Kimberly⁷,St. Rose Earl⁷,Trivedi Roopa⁸,Ballal Shaila⁷,Darken Patrick⁹,Aurivillius Magnus¹⁰,Reisner Colin⁷,Dorinsky Paul⁸

Affiliation:

1. Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, New York

2. LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany

3. Pulmonary Research Institute of Southeast Michigan, Farmington Hills, Michigan

4. National Heart and Lung Institute, London, United Kingdom

5. Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospitals Trust, Manchester, United Kingdom

6. National Clinical Research Centre for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China

7. AstraZeneca, Morristown, New Jersey

8. AstraZeneca, Durham, North Carolina

9. AstraZeneca, Wilmington, Delaware; and

10. AstraZeneca, Gothenburg, Sweden

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine